How many drugs treat Giant Cell Arteritis?

Drug Landscape tracks 4 marketed treatments for Giant Cell Arteritis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/giant-cell-arteritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Giant Cell Arteritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Giant Cell Arteritis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Giant Cell Arteritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Roactemra	tocilizumab	Roche	Interleukin-6 Receptor Antagonist [EPC]	Interleukin-6 receptor	2010-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
tocilizumab or sarilumab	tocilizumab-or-sarilumab	Pfizer	monoclonal antibody	interleukin-6 receptor
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Giant Cell Arteritis
Generic (originally Schering) · 1 drug in Giant Cell Arteritis
Hannover Medical School · 1 drug in Giant Cell Arteritis
Pfizer · 1 drug in Giant Cell Arteritis
Roche · 1 drug in Giant Cell Arteritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Giant Cell Arteritis:

Cite this brief

Drug Landscape (2026). Giant Cell Arteritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/giant-cell-arteritis. Accessed 2026-06-10.

Giant Cell Arteritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing